AI-Assisted Imaging Detects Skin Cancer Before Visible Signs

Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg, led by Dr. Moritz Ronicke of Uniklinikum Erlangen, have successfully demonstrated that artificial intelligence-assisted imaging can detect basal cell carcinoma before clinical symptoms appear. The feasibility study, published in JAMA Dermatology, marks the first instance of pre-visible diagnosis for the world’s most common skin cancer using a systematic facial screening protocol for high-risk patients. The procedure relies on Line-Field Confocal Optical Coherence Tomography, a hybrid imaging modality that combines optical coherence tomography for tissue depth analysis with confocal microscopy for cellular-level resolution. This integration generates real-time, three-dimensional structural maps of the skin at a micrometer scale, enabling precise visualization of microscopic tumor architecture. By embedding artificial intelligence algorithms into the LC-OCT workflow, clinicians receive instant, color-coded probability assessments for malignancy, allowing rapid identification of suspicious tissue while preserving physician oversight for final diagnosis. Early identification of basal cell carcinoma significantly expands therapeutic options. According to Dr. Ronicke, pre-clinical detection frequently eliminates the need for surgical excision, allowing tumors to be managed with topical medications. This approach not only reduces tissue destruction and scarring but also minimizes risks to critical facial structures such as the eyes and nasal cartilage. While LC-OCT is already standardized for early-stage diagnosis and treatment monitoring, the newly validated SUBSCAN screening protocol represents a substantial advancement in preventive dermatology. Despite the promising results, clinical implementation remains constrained by the procedure’s current time demands and the necessity for expanded sensitivity datasets. Researchers emphasize that optimizing workflow efficiency and validating diagnostic accuracy across broader cohorts will be critical before the method transitions from specialized research to routine clinical practice. If successfully integrated, AI-enhanced LC-OCT screening could redefine early skin cancer management, shifting treatment paradigms toward minimally invasive interventions and improving long-term patient outcomes.